CYP2C19 (CYTOCHROME P450 FAMILY 2 SUBFAMILY C MEMBER

Helicobacter pylori infection is widely prevalent worldwide and increases the risk of peptic ulcer disease, gastritis, and gastric cancer. Antibiotic resistance and individual pharmacokinetic variability lead to failure of eradication therapy [1]. The efficacy of proton pump inhibitors (PPIs) depends on their metabolism by the CYP2C19 enzyme, and genetic polymorphisms significantly influence individual treatment outcomes [2]. This study protocol aims to optimize the H. pylori eradication regimen by implementing personalized PPI dosing based on CYP2C19 genotyping. The study is designed as a prospective, randomized clinical trial, and the outcomes are intended to evaluate eradication success according to CYP2C19 genotypes.